We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · July 27, 2020

Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Untreated Metastatic RCC and Sarcomatoid Features

European Urology Oncology

 

Additional Info

European Urology Oncology
Atezolizumab Plus Bevacizumab Versus Sunitinib for Patients With Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Eur Urol Oncol 2020 Jul 09;[EPub Ahead of Print], BI Rini, RJ Motzer, T Powles, DF McDermott, B Escudier, F Donskov, R Hawkins, S Bracarda, J Bedke, U De Giorgi, C Porta, A Ravaud, F Parnis, E Grande, W Zhang, M Huseni, S Carroll, R Sufan, C Schiff, MB Atkins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading